Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.

abstract：:This study was planned as a phase 3 trial to investigate low-dose fludarabine with or without darbepoetin alfa in older patients with previously untreated or treated chronic lymphocytic leukemia (CLL) and comorbidity. Due to slow recruitment, the study was terminated prematurely after accrual of 97 patients who, on av...

journal_title：Leukemia & lymphoma

authors： Goede V,Busch R,Bahlo J,Chataline V,Kremers S,Müller L,Reschke D,Schlag R,Schmidt B,Vehling-Kaiser U,Wedding U,Stilgenbauer S,Hallek M

更新日期：2016-01-01 00:00:00

abstract：:MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

journal_title：Leukemia & lymphoma

authors： Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

更新日期：2021-01-01 00:00:00

abstract：:Follicular lymphoma is an indolent and usually incurable disease. It has been, therefore, traditionally approached either by watch and wait or with single-agent treatments with the purpose of maintaining a good quality of life for a prolonged time. The emergence of more aggressive regimens including polychemotherapy, ...

journal_title：Leukemia & lymphoma

authors： Feuerlein K,Zucca E,Ghielmini M

更新日期：2009-03-01 00:00:00

abstract：:Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...

journal_title：Leukemia & lymphoma

authors： Nagel S,Venturini L,Meyer C,Kaufmann M,Scherr M,Drexler HG,Macleod RA

更新日期：2011-02-01 00:00:00

abstract：:Acute graft-versus-host-disease (aGVHD) is a frequent and often lethal complication of allogeneic hematopoietic stem cell transplant despite prophylaxis. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody that has evidence of activity in patients with steroid refractory (SR) GVHD. We retrospectively rep...

journal_title：Leukemia & lymphoma

authors： Roddy JV,Haverkos BM,McBride A,Leininger KM,Jaglowski S,Penza S,Klisovic R,Blum W,Vasu S,Hofmeister CC,Benson DM,Andritsos LA,Devine SM,Efebera YA

更新日期：2016-01-01 00:00:00

abstract：:The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,Reading CL

更新日期：1996-10-01 00:00:00

abstract：:Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

journal_title：Leukemia & lymphoma

authors： Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

更新日期：2021-01-11 00:00:00

abstract：:Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT...

journal_title：Leukemia & lymphoma

authors： Salles GA,Pettengell R,Cordoba R,Długosz-Danecka M,Jurczak W,Tilly H

更新日期：2019-07-01 00:00:00

abstract：:A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

journal_title：Leukemia & lymphoma

authors： Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

更新日期：2007-07-01 00:00:00

abstract：:To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to chronic lymphocytic leukemia (CLL), we conducted a systematic review and meta-analysis of published case-control studies. We identified 36 studies which reported on polymorphic variation in 19 genes and CLL ri...

journal_title：Leukemia & lymphoma

authors： Sava GP,Speedy HE,Houlston RS

更新日期：2014-01-01 00:00:00

abstract：:Several techniques developed in recent years provide us with the capability to detect sub-microscopic leukemia during remission. Quantitative polymerase chain reaction (PCR) is thus far the most sensitive assay that is applicable in most patients with acute lymphoblastic leukemia (ALL) of childhood. However, false-pos...

journal_title：Leukemia & lymphoma

authors： Estrov Z,Freedman MH

更新日期：1999-03-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1%), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of ...

journal_title：Leukemia & lymphoma

authors： Economopoulos T,Asprou N,Stathakis N,Papageorgiou E,Dervenoulas J,Xanthaki K,Raptis S

更新日期：1996-03-01 00:00:00

abstract：:The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

journal_title：Leukemia & lymphoma

authors： Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

更新日期：2016-11-01 00:00:00

abstract：:Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

journal_title：Leukemia & lymphoma

authors： Molica S

更新日期：2005-01-01 00:00:00

abstract：:This study was conducted to compare the results of myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT for poor-risk low-grade non-Hodgkin's lymphoma. Eighteen patients received autologous SCT and 15 patients received allogeneic SCT. All autologous patients had chemose...

journal_title：Leukemia & lymphoma

authors： Verdonck LF

更新日期：1999-06-01 00:00:00

abstract：:Expression of the intercellular adhesion molecule-1 (CD54) as well as the mutations of p53 gene were studied in childhood Burkitt's lymphoma (BL). Expression of CD54 was identified in 6 of 15 fresh BL cases. Mutations of p53 gene, analyzed by polymerase chain reaction-single stranded chain polymorphism followed by seq...

journal_title：Leukemia & lymphoma

authors： Kaneko H,Sugita K,Kiyokawa N,Iizuka K,Takada K,Saito M,Yoshimoto K,Itakura M,Kokai Y,Fujimoto J

更新日期：1996-05-01 00:00:00

abstract：:Data from the large, prospective, multinational, phase 3b JUMP study were analyzed to identify factors predictive of spleen and symptom responses in myelofibrosis patients receiving ruxolitinib. Factors associated with higher spleen response rates included International Prognostic Scoring System (IPSS) low/intermediat...

journal_title：Leukemia & lymphoma

authors： Gupta V,Griesshammer M,Martino B,Foltz L,Tavares R,Al-Ali HK,Giraldo P,Guglielmelli P,Lomaia E,Bouard C,Paley C,Tiwari R,Zor E,Raanani P

更新日期：2020-11-19 00:00:00

abstract：:Recent data suggest that myeloid neoplasms are organized hierarchically in terms of self-renewal and maturation of early progenitor cells, similar to normal myelopoiesis. In acute myeloid leukemia (AML), the NOD/SCID mouse-repopulating leukemic stem cells usually co-express CD123 with CD34, but lack CD38. So far, howe...

journal_title：Leukemia & lymphoma

authors： Florian S,Sonneck K,Hauswirth AW,Krauth MT,Schernthaner GH,Sperr WR,Valent P

更新日期：2006-02-01 00:00:00

abstract：:Arsenic trioxide (As2O3) is currently employed as a treatment for relapsed acute promyelocytic leukemia (APL), where it can induce remission in greater than 90% of patients, but is ineffective in patients with non-APL acute myeloid leukemia (AML). As2O3 induces apoptosis in APL cells through mechanisms dependent and i...

journal_title：Leukemia & lymphoma

authors： Coe E,Schimmer AD

更新日期：2008-10-01 00:00:00

abstract：:Herbal remedies are clearly a complementary and alternative modality used frequently by patients with hemato-oncological neoplasias during the course of their specific treatment. This review focuses on the potential safety and efficacy of herbs which are either used often or even on a daily basis by patients with hema...

journal_title：Leukemia & lymphoma

authors： Ben-Arye E,Attias S,Tadmor T,Schiff E

更新日期：2010-08-01 00:00:00

abstract：:A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

journal_title：Leukemia & lymphoma

authors： Bompas E,Velay B,Blay JY

更新日期：2004-11-01 00:00:00

abstract：:Tumor necrosis factor (TNF) is a major regulator of AML growth in vitro and markedly enhances AML growth induced by GM-CSF/IL-3. TNF, on the other hand, suppresses the G-CSF stimulated AML cell proliferation and serves as a modulator of growth factor receptors on AML cells. It upregulates GM-CSF and IL-3 receptors by ...

journal_title：Leukemia & lymphoma

authors： Elbaz O,Mahmoud LA

更新日期：1994-01-01 00:00:00

abstract：:Twenty-six non-Hodgkin's malignant lymphomas (ML) of the Waldeyer's ring, the mouth and nasal cavities were studied morphologically and immunohistochemically on paraffin and frozen sections. A B-cell origin was shown in all 14 cases of Waldeyer's ring M.L., while 5 of 7 nasal and 3 of 5 buccal cases were of T-cell nat...

journal_title：Leukemia & lymphoma

authors： Papadimitriou CS,Bai MK

更新日期：1991-01-01 00:00:00

abstract：:High-dose therapy followed by autologous stem cell transplantation (ASCT) has been considered a potential treatment approach in order to improve the poor prognosis in mantle cell lymphoma (MCL), but its role has not yet been clearly established. We analyzed retrospectively the outcome and prognostic factors in 48 cons...

journal_title：Leukemia & lymphoma

authors： Oinonen R,Jantunen E,Itälä M,Lehtinen T,Kuittinen O,Franssila K,Wiklund T,Elonen E

更新日期：2002-06-01 00:00:00

abstract：:The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...

journal_title：Leukemia & lymphoma

authors： Manasanch EE,de Larrea CF,Zingone A,Steinberg SM,Kwok M,Tageja N,Bhutani M,Kazandjian D,Roschewski M,Wu P,Carter G,Zuchlinski D,Mulquin M,Lamping L,Costello R,Burton D,Gil LA,Figg WD,Maric I,Calvo KR,Yuan C,Stet

更新日期：2017-03-01 00:00:00

abstract：:B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

journal_title：Leukemia & lymphoma

authors： Jabbar SA,Hoffbrand AV,Wickremasinghe RG

更新日期：1995-06-01 00:00:00

abstract：:Peripheral blood progenitor cells are being used increasingly as part of the treatment protocol for a variety of haematological malignancies. The most appropriate mobilisation therapy and the optimum collection procedures have yet to be fully elucidated. 28 patients with myeloma (9), NHL (11) and HD (8) underwent PBSC...

journal_title：Leukemia & lymphoma

authors： Scott MA,Ager S,Apperley JF,Jestice HK,Bloxham DM,Boraks P,Mahendra P,Marcus RE

更新日期：1995-11-01 00:00:00

abstract：:Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% (n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletio...

journal_title：Leukemia & lymphoma

authors： Kathiravan M,Singh M,Bhatia P,Trehan A,Varma N,Sachdeva MS,Bansal D,Jain R,Naseem S

更新日期：2019-02-01 00:00:00

abstract：:Myeloproliferative neoplasms (MPNs) are associated with pulmonary hypertension (PH). We studied MPN patients who underwent right-heart-catheterization (RHC) to identify hemodynamic differences between MPN-subtypes. Per RHC, hemodynamics were classified as pre, post or combined pre and post-capillary PH. One-way analys...

journal_title：Leukemia & lymphoma

authors： Khan NA,Ahuja KA,Wang X,Chaisson NF

更新日期：2021-01-25 00:00:00